Withdrawn applications and products
HumanCOVID-19
Vaccine developers have withdrawn the marketing authorisation for the following COVID-19 vaccines:
| Vaccine | Vaccine developer | Key milestones | More information |
|---|---|---|---|
| COVID-19 Vaccine (inactivated, adjuvanted) Valneva | Valneva Austria GmbH | Marketing authorisation issued: 24/06/2022 Withdrawal of the marketing authorisation: 12/10/2023 | Public statement on COVID-19 Vaccine (inactivated, adjuvanted) Valneva |
| Vaxzevria (previously COVID-19 Vaccine AstraZeneca) | AstraZeneca AB | Conditional marketing authorisation issued: 29/01/2021 Annual renewal issued: 09/11/2021 Standard marketing authorisation issued: 31/10/2022 Withdrawal of the marketing authorisation: 27/03/2024 | Public statement on Vaxzevria (previously COVID-19 Vaccine AstraZeneca) |
| VidPrevtyn Beta | Sanofi Pasteur | Marketing authorisation issued: 10/11/2022 Withdrawal of the marketing authorisation: 11/03/2024 | Public statement on VidPrevtyn Beta |
| Jcovden (previously COVID-19 Vaccine Janssen) | Janssen-Cilag International NV | Conditional marketing authorisation issued: 11/03/2021 Annual renewal issued: 03/01/2022 Standard marketing authorisation issued: 10/01/2023 Withdrawal of the marketing authorisation: 09/08/2024 | Public statement on Jcovden (COVID-19 Vaccine Janssen (Ad26.COV2.S) |
COVID-19 vaccines withdrawn from rolling review
Vaccine developers have withdrawn the following COVID-19 vaccines from the rolling review process:
| Vaccine | Vaccine developer | Key milestones | More information |
|---|---|---|---|
| CVnCoV | CureVac AG | Rolling review started: 12/02/2021 Withdrawn from rolling review: 12/10/2021 |
Vaccine developers have withdrawn the following COVID-19 vaccines from the marketing authorisation evaluation process:
| Vaccine | Vaccine developer | Key milestones | More information |
|---|---|---|---|
| Skycovion | SK Chemicals GmbH | Marketing authorisation evaluation started: 18/08/2022 Withdrawn from marketing authorisation evaluation: 01/09/2023 | Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 September 2023 |
Treatment developers have withdrawn the following COVID-19 treatments from the marketing authorisation evaluation process:
| Treatment | Treatment developer | Key milestones | More information |
|---|---|---|---|
| Olumiant (baricitinib) | Eli Lilly Nederland B.V. | Marketing authorisation evaluation started: 23/11/2021
Withdrawn from marketing authorisation evaluation: 07/12/2022 | Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 December 2022
|
| Lagevrio (molnupiravir) | Merck Sharp & Dohme and Ridgeback Biotherapeutics | Marketing authorisation evaluation started: 23/11/2021 CHMP negative opinion: 23/02/2023 Re-examination request submitted: 13/03/2023 Withdrawn from marketing authorisation evaluation: 21/06/2023 |
COVID-19 treatments withdrawn from rolling review
Treatment developers have withdrawn the following COVID-19 treatments from the rolling review process:
| Treatment | Treatment developer | Key milestones | More information |
|---|---|---|---|
| Bamlanivimab and etesevimab | Eli Lilly | Rolling review started: 11/03/2021
Withdrawn from rolling review: 29/10/2021 | Latest news |